Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has announced its upcoming participation in the Stifel 2025 Virtual Targeted Oncology Forum. CEO Michael A. Metzger and other management team members will engage in a fireside chat scheduled for Wednesday, April 9, 2025, at 10:30 a.m. ET. The event will be accessible via live webcast through the company's website investor section, with a replay option available for a time.
Details
News Market Reaction – SNDX
The recorded move for SNDX in the trading session of this news was +7.99%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET.
A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.